Targeting myeloid derived suppressor cells reverts immune suppression and sensitizes BRAF-mutant papillary thyroid cancer to MAPK inhibitors

MAPK signaling inhibitor (MAPKi) therapies show limited efficacy for advanced thyroid cancers despite constitutive activation of the signaling correlates with disease recurrence and persistence. Understanding how BRAF pathway stimulates tumorigenesis could lead to new therapeutic targets. Here, thro...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Peitao, Guan, Haixia, Yuan, Shukai, Cheng, Huili, Zheng, Jian, Zhang, Zhenlei, Liu, Yifan, Yu, Yang, Meng, Zhaowei, Zheng, Xiangqian, Zhao, Li
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8948260/
https://www.ncbi.nlm.nih.gov/pubmed/35332119
http://dx.doi.org/10.1038/s41467-022-29000-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8948260/
https://www.ncbi.nlm.nih.gov/pubmed/35332119
http://dx.doi.org/10.1038/s41467-022-29000-5

Ejemplares similares